The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.

Condition	Treatment or Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine/naloxone	Phase III

Further Study Details: 

Expected Total Enrollment:  221

Ages Eligible for Study:  14 Years   -   21 Years,  Genders Eligible for Study:  Both

Criteria

Male and non-pregnant female subjects seeking outpatient treatment for opioid dependence with physiological features without serious medical or psychiatric disorders.

Sabrina Poole      (215)399-0980  Ext. 118    spoole@tresearch.org

Delaware
      Brandywine Counseling Center, Wilmington,  Delaware,  19805,  United States; No longer recruiting
Maine
      Mercy Hospital, Portland,  Maine,  04092,  United States; Recruiting
Maryland
      Mountain Manor, Baltimore,  Maryland,  21229,  United States; Recruiting
New Mexico
      ASAP, Albuquerque,  New Mexico,  87106,  United States; Recruiting
      Ayudantes, Santa Fe,  New Mexico,  87505,  United States; No longer recruiting
North Carolina
      Duke Addictions Program, Durham,  North Carolina,  27710,  United States; Recruiting

Study chairs or principal investigators

George Woody, M.D.,  Principal Investigator,  University of Pennsylvania   

Study ID Numbers:  NIDA-CTN-0010-1
Record last reviewed:  April 2005
Last Updated:  April 7, 2005
Record first received:  February 19, 2004
ClinicalTrials.gov Identifier:  NCT00078130
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08